To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

NCT05818982 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Afatinib
DRUG: Irinotecan

Sponsor

Peking University